The Cystic Fibrosis Foundation, European Cystic Fibrosis Society, and Cystic Fibrosis Europe provided comments to the European Medicines Agency on draft guidance on establishing efficacy of a new treatment based on single-arm trials.
Site Search
CF Foundation letter thanking Michigan’s governor for providing adequate funding for the Children’s Special Health Care Services program and Medicaid in the state’s 2024 budget, both of which play an important role in ensuring consistent access to care for Michiganders living with CF.
Ad hoc patient coalition provides comments to the U.S. Department of Health and Human Services supporting Washington’s proposal to extend continuous eligibility to the Children’s Health Insurance Program to children under six years of age in the state.
CF Foundation letter to Michigan’s Committee on Insurance and Financial Services supporting HB 4719, which would require insurers to apply third party assistance to out-of-pocket maximums and other patient cost-sharing requirements.
CF Foundation letter thanking the California Department of Health Care Services for including certain CF medications on the state's list of medications eligible for extended duration prior authorization under Medi-Cal Rx and requesting the inclusion of additional medications to that list.
Ad hoc coalition comment letter to HHS opposing a proposal to implement Medicaid work requirements in Arkansas.
The Foundation sends a letter to leaders of the House Energy & Commerce Committee urging passage of H.R. 3008, 3793 and 3810 which would help mitigate drug shortages and ensure patients will have access to all necessary medications.
CF Foundation letter to New York’s governor asking that she sign a bill that would reinstate the Adult CF Assistance Program.
The Cystic Fibrosis Foundation along with directors of Colorado's Cystic Fibrosis care centers sent a letter to the state's Prescription Drug Affordability Board commenting on the list of prioritized drugs eligible for an affordability review.
In its response, sent to the U.S. House of Representatives Budget Committee Health Care Task Force, the Foundation commented on how legislation to combat the antimicrobial resistance crisis, such as the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (H.R.